Background: Nausea and vomiting are the most frequent side effects of opioids and may cause the opioids to be discontinued. New methods for preventing opioid-induced nausea can improve cancer pain management. Oxycodone is one of the most frequently used opioid used in Japan because patients receiving oxycodone report less nausea and vomiting than do patients receiving morphine. The reported incidence of oxycodone-induced nausea varies widely, although the true incidence remains unclear. As a first step toward preventing oxycodone-induced nausea, we aimed to determine the incidence of and risk factors for oxycodone-induced nausea and vomiting.
Introduction
Nausea and vomiting, together with constipation and drowsiness, are the most frequent side effects of opioids 1 , and such side effects may even lead to the discontinuation of opioid use and compromise pain management 2 .
Although many patients have opioid-induced nausea and vomiting, with approximately 10% reporting nausea as the most bothersome symptom 3 , antiemetics are often administered only when symptoms appears rather than prophylactically, because the incidence of opioid-induced nausea and vomiting is thought to be low 1 . On the other hand, preventing opioid-induced nausea can improve the treatment of cancer pain and enhance quality of life 4 .
However, is the incidence of opioid-induced nausea and vomiting actually low? Is there no need to prevent opioid-induced nausea and vomiting?
To find answer these questions, we need to know the incidence of opioid-induced nausea and vomiting. Oxycodone is one of the most frequently used opioid in Japan because patients receiving oxycodone report less nausea and vomiting than do patients receiving morphine 5, 6 . According to previous studies, the incidence of oxycodone-induced nausea in patients with cancer who have not received any preventive antiemetic agent is 13.3% to 51.9% 2,6 9 . However, 4 of these 5 studies included fewer than 30 patients, and the results are controversial.
The incidence derived from these 5 studies varies widely, and the true incidence remains unclear.
As a result we aimed to determine the incidence of oxycodone-induced nausea and vomiting. In Japan, prochlorperazine is usually administered to prevent opioidinduced nausea and vomiting 10 ; thus, we intended to determine the incidence of nausea and vomiting induced by oxycodone when administered with prochlorperazine.
In this observational study, the primary endpoint was to understand the incidence of nausea and vomiting, while the secondary endpoint was to identify risk factors for oxycodone-induced nausea and vomiting.
Patients and Methods

Patients
We prospectively evaluated a series of consecutive patients with cancer who were given controlled-release oxy- with prochlorperazine, 5) confirmed diagnosis of moderate-to-severe cancer pain (Numeric Rating Scale " 4), 6) good oral intake, and 7) management with a clinical pathway. Exclusion criteria were as follows: 1) administration of antiemetic agents other than prochlorperazine, 2) schizophrenia or dementia, 3) paralytic ileus, 4) hepatic impairment, 5) severe renal dysfunction, 6) administration of other long-acting opioids during the study period, 7) undergoing chemotherapy, and 8) death within 3 days after starting oxycodone.
Treatment
We managed the patients with a clinical pathway to avoid missing medications and to facilitate observation.
We administered oxycodone (5 mg) either at 08:00 and 20:00 or at 09:00 and 21:00 (total 10 mg! day) and pro- If patients had sudden breakthrough pain more than twice a day during treatment, increasing the dose of the next administration was considered. For patients who were given 5 mg, the treatment dose could be directly increased to 10 mg. For patients who were given " 10 mg, the treatment dose could be increased by 25% to 50% of the current dose at each increase. This dose titration was continued until adequate pain control was achieved.
Pain control was considered adequate when the following conditions were fulfilled: the dose every 12 hours was unchanged, immediate-release oxycodone was used fewer than 3 times per day, the dosing regimen for any nonopioids was unchanged, the patients rated their pain intensity with a Numeric Rating Scale score of <4, and any adverse events were tolerable.
Sample Size
On the basis of our previous retrospective study, we predicted that the incidence of nausea would be 15%.
Power calculations indicated that 137 patients were required as study participants when we set 95% confidence intervals (CIs) with a 6% error. We predicted that some participants would drop out. In total, 145 consecutive patients were enrolled.
Evaluations
We defined "nausea" as an unpleasant and emergent urge to vomit, "vomiting" as a reflexive expulsion of digestive contents, and "gastrointestinal distress" as abdominal discomfort and stomach pain. The patients were asked to assess their nausea, drowsiness, and gastrointestinal distress twice each day (morning and bedtime) and recorded "yes" or "no" with the assistance of research nurses for 5 days. To ensure that records were complete, every morning research nurses confirmed their records of the previous day. The patients were also asked twice daily to assess the acceptability of therapy with consideration of their pain intensity during the previous 12-hour period. Constipation was regarded as a stool-free interval of more than 72 hours during the 5 days. Vomiting was judged by the research nurses or investigators.
The primary endpoint of this study was the incidence and 95% CI of nausea caused by administration of 10 mg of oxycodone in opioid-naïve patients with cancer who were given prochlorperazine to prevent nausea and vomiting. The percentages of nausea and vomiting were analyzed with the Clopper-Pearson method and a 95% CI.
The secondary endpoint was the identification of risk factors for nausea and vomiting. The incidence rates of nausea and vomiting were compared by means of the chisquare test between men and women, between elderly (" 70 years of age) and younger patients, and between patients with digestive system cancer and those with nondigestive system cancer. A P value of <0.05 was considered to indicate statistical significance. All analyses were performed with the software package IBM SPSS Statistics Base, version 20 (IBM Japan Ltd., Tokyo, Japan).
Results
A total of 163 patients were given oxycodone and managed with a clinical pathway. Eighteen patients were excluded because they were not receiving prochlorperazine or were given other preventive antiemetic agents on day 1. According to our plan, we enrolled 145 consecutive patients in this study. However, 2 patients were excluded because prochlorperazine was not administered after day 2, and 5 patients were excluded because they died within 3 days of starting oxycodone. A total of 138 patients were included, of which none had previously used another opioid.
The mean age of patients was 67.2 years (range, 33 94 years), and the male-to-female ratio was 93 : 45 ( Table 1 ).
The primary site of cancer was the digestive system in nearly three-quarters of the study patients (101 patients, 73.2%; Table 2 ). The average administered dose on the last day of the study was 16.8 mg (range, 10 60 mg), and about two-thirds (66.8%) of patients treated with 10 mg! day of oxycodone experienced a good analgesic effect for 5 days.
The most frequent adverse effect was sleepiness, with an incidence of 34.1% (95% CI, 26.2 42.0; Table 2 ). The incidence of nausea was 18.1% (95% CI, 11.6 24.5), and that of vomiting was 5.8% (95% CI, 1.9 9.7; Table 3 ). The incidence of nausea was higher, but not to a significant degree, in women than in men, (P=0.07; Table 4 ). Moreover, the incidence of vomiting in women was equal to that of men (P=0.28) ( Table 4) , whereas the incidences of both nausea (P=0.99) and vomiting (P=0.89) in elderly patients were equal to those in younger patients ( Table   4 ). The incidences of both nausea (P=0.52) and vomiting (P=0.91) in patients with digestive system cancer were equal to those in patients with non-digestive system cancer ( Table 4) .
Discussion
This study is, to our knowledge, the first to evaluate the incidence of oxycodone-induced nausea and vomiting when oxycodone is administered with prochlorperazine to opioid-naïve patients. The incidence of nausea was 18.1% (95% CI, 13.9 23.4%), and that of vomiting was 5.8% (95% CI, 3.8 7.8%).
Several small-scale studies (with 20 to 27 patients) and one large-scale study (with 1,823 patients) have previously investigated oxycodone-induced nausea and vomiting 2,6 9 . In these studies, the incidence of nausea was 13.3% to 51.9%. Oxycodone-induced nausea and vomiting most often begins on the first administration of oxycodone to 5 days afterwards. To evaluate the exact incidence of oxycodone-induced nausea, we interviewed patients twice a day for 5 days because patients are sometimes not able to recall their experiences clearly. In contrast, patients in the largest previous study were evaluated every week for 8 weeks 9 . In any case, more than 10% of the patients with cancer who used oxycodone for pain relief had oxycodone-induced nausea. These findings suggest that a new preventive treatment for oxycodone-induced nausea is needed.
Female sex may be a risk factor for oxycodone-induced nausea. Indeed, the incidence of nausea in female patients was higher than that in male patients, although the difference was not significant (P=0.07). However, power calculations indicated that 348 patients (174 in each group) would be required to achieve a power of 90% with a 2-sided alpha value of 0.05 to demonstrate a sex difference. Therefore, this study was underpowered to validate the difference in this prevalence. A study including more than 1,000 participants found that opioids had a stronger analgesic effect in female patients than in male patients 11 , suggesting that the adverse effects of opioids may also be stronger in female patients than in male patients.
The present study did not identify digestive system cancer as a risk factor for oxycodone-induced nausea and vomiting. We had expected digestive symptoms, including nausea and vomiting, to be amplified in patients
with digestive system cancer. However, we found that the incidence of nausea and vomiting in patients with digestive system cancer was equal to that of patients with non-digestive system cancer. Furthermore, we had expected the rate of nausea and vomiting to be higher in elderly patients than in younger patients because the blood concentration of oxycodone may be higher in elderly patients than in younger patients. However, we found that the incidence of nausea and vomiting was equal in the 2 age groups. Thus, old age was also not a risk factor of oxycodone-induced nausea and vomiting. Opioid-induced nausea is mediated by dopamine, histamine, and serotonin; therefore, their respective antagonists can prevent opioid-induced nausea 1 . Prochlorperazine cannot prevent nausea caused by histamine because prochlorperazine inhibits mainly dopamine receptors. In this study, nausea in approximately half of patients was alleviated by chlorpheniramine maleate, which inhibits histamine receptors (data not shown).
To reduce the incidence of opioid-induced nausea, agents that inhibit dopamine and histamine in a balanced manner are required. For example, olanzapine, which blocks multiple neurotransmitters, including dopaminergic, serotonergic, adrenergic, histaminergic, and muscarinic receptors 16 , is a strong candidate for future usage.
In a ferret model, olanzapine decreased opioid-induced nausea and vomiting in a dose-dependent manner 17 . Coadministration of prochlorperazine, which inhibits dopamine receptors, and diphenhydramine, which inhibits histamine receptors, is another candidate for a balanced therapeutic effect. The results of the present study can serve as a baseline for new studies to develop therapies to prevent oxycodone-induced nausea.
This study has several limitations. First, our observations were conducted over a period of only 5 days. However, adverse events, including constipation, nausea, and vomiting, are noted most frequently in the first week and decrease over time 18 . Thus, it is unlikely that the short observation period caused the incidence of nausea to be underdiagnosed. Second, this study included only inpatients, who were managed by many physicians and nurses with adequate attention, rather than outpatients, who may have a higher incidence of nausea. Third, our study included only opioid-naïve patients who received only 10 mg! day of oxycodone. Indeed, the incidence of nausea may be higher in patients given a higher dose of oxycodone.
In conclusion, the incidence of nausea induced by oxycodone administered with prochlorperazine was 18.1% in opioid-naïve Japanese inpatients. Female patients may be at a higher risk for oxycodone-induced nausea and vomiting. Studies with larger numbers of patients (300 or more) should be performed to evaluate new therapies for preventing oxycodone-induced nausea and vomiting.
Equal numbers of male and female patients should be included in each treatment group, but less crucial are the ratio of elderly to younger patients and the ratio of patents with digestive system cancer to those with nondigestive system cancer.
